Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.73 per share in its upcoming report, which indicates a year-over-year increase of 231.1%. Revenues are expected to ...

Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

The market expects Gilead Sciences (GILD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Hulu's spinoff of 'The Handmaid's Tale' titled 'The Testaments' comes after the original show's sixth and final season ...

The Handmaid’s Tale Season 6 finale is just a few weeks away, but fans hoping for a neatly wrapped story to June Osbourne and ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...

As the final season of "The Handmaid's Tale" begins today, we're taking a look back on everything to know about the hit Hulu ...

"It's not about a relationship she chose, like with Fred," Bruce Miller says, explaining why writers chose to introduce the ...

On The Handmaid's Tale Season 6 Episode 4 Joseph gets a promotion for his reforms while the resistance plans a major assault ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...